Investigational drug · Phase 3
Obicetrapib
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
7 still active
All registered trials
21
Any phase or sponsor naming "Obicetrapib"
First trial start
2022
Feb 7, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Obicetrapib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lipidemia
- Preclinical Alzheimer's Disease
- Antioxidant Absorption
- Coronary Artery Disease
- Plaque, Atherosclerotic
- Type 2 Diabetes (T2DM)
- Metabolic Syndrome (MetS)
- Atherosclerotic Cardiovascular Disease
- Dyslipidemias
- Mixed Dyslipidemia
Approved drugs for the same conditions: Type 2 diabetes · Coronary artery disease and heart attack · Alzheimer's disease · Cardiovascular and metabolic · Neurology · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Obicetrapib" as an intervention, largest first.
- Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular DiseasePivotal-lookingActive, not recruiting
NewAmsterdam PharmaIndustry
NCT05202509 · 9,541 participants · Start Feb 7, 2022 · Primary completion Nov 2026
Drug: Obicetrapib; Placebo · For: Atherosclerotic Cardiovascular Disease
Sites: Alexander City, Alabama; Birmingham, Alabama; Fairhope, Alabama · 591 sites in all
- Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying TherapiesPivotal-lookingCompleted
NewAmsterdam PharmaIndustry
NCT05142722 · 2,530 participants · Start Dec 15, 2021 · Primary completion Sep 26, 2024
Drug: Placebo; Obicetrapib · For: Dyslipidemias; High Cholesterol; Hypercholesterolemia and 2 more
Sites: Anniston, Alabama; Birmingham, Alabama; Saraland, Alabama · 181 sites in all
A. Menarini International Licensing S.A.Industry
NCT07614958 · 426 participants (planned) · Start May 6, 2026 · Primary completion Jan 2027
Drug: Obicetrapib 10 mg/Bempedoic Acid Placebo; Bempedoic Acid 180mg/Placebo Obicetrapib · For: Mixed Dyslipidemia; Hypercholesterolaemia
Sites: Stockton-on-Tees, United Kingdom
- Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying TherapiesPivotal-lookingCompleted
NewAmsterdam PharmaIndustry
NCT06005597 · 407 participants · Start Mar 1, 2024 · Primary completion Sep 25, 2024
Drug: Monotherapy obicetrapib; Monotherapy ezetimibe · For: Dyslipidemias; Hypercholesterolemia; Familial Hypercholesterolemia and 2 more
Sites: Gilbert, Arizona; Jacksonville, Florida; Port Orange, Florida · 45 sites in all
- Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's DiseasePivotal-lookingRecruiting
NewAmsterdam PharmaIndustry
NCT07794670 · 400 participants (planned) · Start Sep 2026 · Primary completion Sep 2028
Drug: Obicetrapib 10 mg; Matching placebo tablets · For: Preclinical Alzheimer's Disease
Sites: Nashville, Tennessee
- Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.Pivotal-lookingCompleted
NewAmsterdam PharmaIndustry
NCT05425745 · 354 participants · Start Jul 25, 2022 · Primary completion May 28, 2024
Drug: Obicetrapib; Placebo · For: Dyslipidemias; High Cholesterol; Hypercholesterolemia and 6 more
Sites: Jonesboro, Arkansas; Toluca Lake, California; Sarasota, Florida · 96 sites in all
- A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary PlaquePivotal-lookingActive, not recruiting
NewAmsterdam PharmaIndustry
NCT06305559 · 300 participants (planned) · Start May 16, 2024 · Primary completion Nov 2027
Drug: obicetrapib 10 mg + ezetimibe 10 mg FDC daily · For: Lipidemia; Coronary Artery Disease; Plaque, Atherosclerotic
Sites: Hialeah, Florida
- A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic SyndromePivotal-lookingActive, not recruiting
NewAmsterdam PharmaIndustry
NCT07219602 · 300 participants (planned) · Start Dec 11, 2025 · Primary completion Mar 2028
Drug: obicetrapib 10 mg + ezetimibe 10 mg FDC daily; Obicetrapib 10 mg · For: Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS)
Sites: Sun City West, Arizona; La Jolla, California; Pomona, California · 55 sites in all
- Randomized Study of Obicetrapib as an Adjunct to Statin TherapyPivotal-lookingCompleted
NewAmsterdam PharmaIndustry
NCT04753606 · 120 participants · Start Feb 18, 2021 · Primary completion May 24, 2021
Drug: Obicetrapib · For: Dyslipidemias; High Cholesterol; Hypercholesterolemia
Sites: Anniston, Alabama; Huntington Park, California; Los Angeles, California · 19 sites in all
- Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS TherapyPivotal-lookingCompleted
NewAmsterdam PharmaIndustry
NCT05266586 · 119 participants · Start Mar 9, 2022 · Primary completion Aug 12, 2022
Drug: Obicetrapib; Ezetimibe 10mg · For: Dyslipidemias; High Cholesterol; Hypercholesterolemia
Sites: Los Angeles, California; Northridge, California; Ocala, Florida · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Cholesteryl ester transfer protein inhibition: from LDL lowering to dementia prevention.
de Kleer MAC, Ditmarsch M, Kastelein JJP · Curr Opin Lipidol 2026
- Comparative biomarker efficacy of cholesteryl ester transfer protein inhibitors: a network meta-analysis.
Banach M, Jaiswal V, Ang SP, et al. · Eur Heart J Cardiovasc Pharmacother 2026
- Efficacy and Safety of Oral Non-Statin Lipid-Lowering Therapies in Dyslipidaemia: A Systematic Review and Network Meta-Analysis.
Hodrob T, Saad RJ, Hamdy A, et al. · Endocrinol Diabetes Metab 2026
- Effect of Obicetrapib on Glycaemia and New-Onset Diabetes: Pooled Analysis of BROADWAY/BROOKLYN and an Updated Meta-analysis of CETP Inhibitor Trials.
Brandts J, Szarek M, Nicholls SJ, et al. · Eur J Prev Cardiol 2026
- Beyond Traditional Lipid Lowering: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein Inhibition.
Thandi P, Pradhan A, Agarwala R, et al. · Eur Cardiol 2026
- Obicetrapib-ezetimibe combination therapy: a novel oral strategy for enhanced lipid lowering.
Chitsazan M, Chitsazan M, Cannon CP · Cardiovasc Res 2026
Also in development for Lipidemia
- ezetimibe FDCPhase 32 trials
NewAmsterdam Pharma · Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.